endovastec™ joined icarus 2021 symposium2021-云顶国际

warsaw, poland—recently, shanghai microport endovascular medtech(group) co., ltd. (“endovastec™”), participated in the 2021 interventional endovascular case review european symposium (icarus) at the invitation of the organizers.

as an influential endovascular symposium in europe, the annual icarus invites globally recognized endovascular experts to join in academic exchange on complex and challenging cases. endovastec™ held an academic forum during the symposium focusing on the clinical experience of the minos™ abdominal aortic stent-graft and delivery system (“minos™”), and castor™ branched aortic stent-graft system (“castor™”). prof. grzegorz oszkinis, chairman of the symposium and director of vascular surgery department at university hospital of opole, prof. piotr gutowski, director of vascular surgery department at university hospital in szczecin, and prof. chang shu, director of vascular surgery center of fuwai hospital of chinese academy of medical sciences, national center for cardiovascular diseases join in the discussion.

prof. oszkinis introduced a clinical case where minos™ was applied and clinical data from the center was also shared. the patient, a 68-year-old male, was admitted to the hospital with a complaint of pain. preoperative ct results showed an abdominal aortic aneurysm with a maximum diameter of 61 mm and narrow vessel access, which was challenging for introduction of the delivery system. such an assessment led the expert team to decide to use the minos™ stent for treatment. prof. oszkinis noted that the minos™ stent has been successfully implanted at the university hospital of opole in 18 patients suffered from dominal aortic aneurysms with favorable follow-up results. the delivery system of minos™ has a smaller outer sheath diameter of 14 fr, which reduces the diameter requirement of the access vessel and avoids complications related to the challenging anatomies of the access artery. minos™ owns excellent performance in compliance and wall apposition so as to reduce the incidence of endoleak and re-intervention, providing promising clinical results.

prof. gutowski shared three clinical cases applied with castor™ stent. he commented that castor™ is an excellent product for aortic arch lesions, offering multiple advantages such as precise release and shorter procedure time compared to parallel stent graft techniques. prof. gutowski also shared some key operation skills drawn from his own experience. 

prof. shu exchanged his viewpoints on clinical strategy of endovascular treatment for thoracic disease with the two polish experts focusing on clinical experience of castor™ in china. during the meeting, experts agreed on the advantages of castor™ for the treatment of aortic arch lesions, 

1.the integrated single-branch structure can effectively reduce the surgical difficulty of reconstructing multi-branch vessels on the arch. 

2.castor™ lowers the incidence of stroke and spinal cord injury due to blockage of the left subclavian artery. 

3.castor™ avoids the risk of gutter endoleak associated with the chimney technique and long-term migration associated with the fenestration technique. 

during the forum, prof. shu also had an in-depth exchange with experts from the united states, focusing on ethnographic variations and clinical experience of minos™ and castor™. prof. shu noted that, for a long time, china has been learning from western experience and technology in the area of aortic interventional devices. however, in recent years, chinese doctors and engineers closely cooperated and have been able to develop innovative medical devices such as minos™ and castor™ that can be better adapted to anatomies and pathologies of chinese patients. these innovative products also provide good solutions for overseas doctors and patients.

in the future, endovastec™ will continue to promote academic exchanges among global vascular experts and deepen medical-industrial cooperation. endovastec™ is committed to introducing more innovative high-tech medical devices into the global market, so as to benefit more patients and doctors with an inclusive “chinese solution”.